Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Amycolatopsis mediterranei

ABSTRACT: Antibiotic producing bacterium

PROVIDER: PRJNA43575 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR1642853.fastq.gz	Fastqsanger.gz
	SRR1644035.fastq.gz	Fastqsanger.gz
	SRR1644037.fastq.gz	Fastqsanger.gz
	SRR1644038.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 9

Similar Datasets

Amycolatopsis mediterranei S699

Project description:Comparative genomics reveals new molecular targets for accelerated strain improvement of rifamycin B-producing strains

| PRJNA219644 | ENA

Rifamycin W Analogues from Amycolatopsis mediterranei S699 Δrif-orf5 Strain.

Project description:Rifamycin W, the most predominant intermediate in the biosynthesis of rifamycin, needs to undergo polyketide backbone rearrangement to produce rifamycin B via an oxidative cleavage of the C-12/C-29 double bond. However, the mechanism of this putative oxidative cleavage has not been characterized yet. Rif-Orf5 (a putative cytochrome P450 monooxygenase) was proposed to be involved in the cleavage of this olefinic moiety of rifamycin W. In this study, the mutant strain Amycolatopsis mediterranei S699 Δrif-orf5 was constructed by in-frame deleting the rif-orf5 gene to afford thirteen rifamycin W congeners (1-13) including seven new ones (1-7). Their structures were elucidated by extensive analysis of 1D and 2D NMR spectroscopic data and high-resolution ESI mass spectra. Presumably, compounds 1-4 were derivatized from rifamycin W via C-5/C-11 retro-Claisen cleavage, and compounds 1-3, 9 and 10 featured a hemiacetal. Compounds 5-7 and 11 showed oxygenations at various sites of the ansa chain. In addition, compounds 1-3 exhibited antibacterial activity against Staphylococcus aureus with minimal inhibitory concentration (MIC) values of 5, 40 and 0.5 µg/mL, respectively. Compounds 1 and 3 showed modest antiproliferative activity against HeLa and Caco-2 cells with half maximal inhibitory concentration (IC50) values of about 50 µM.

| S-EPMC8301457 | biostudies-literature

CRISPR-Cas12a-Assisted Genome Editing in <i>Amycolatopsis mediterranei</i>.

Project description:Amycolatopsis mediterranei U32 is an industrial producer of rifamycin SV, whose derivatives have long been the first-line antimycobacterial drugs. In order to perform genetic modification in this important industrial strain, a lot of efforts have been made in the past decades and a homologous recombination-based method was successfully developed in our laboratory, which, however, requires the employment of an antibiotic resistance gene for positive selection and did not support convenient markerless gene deletion. Here in this study, the clustered regularly interspaced short palindromic repeat (CRISPR) system was employed to establish a genome editing system in A. mediterranei U32. Specifically, the Francisella tularensis subsp. novicida Cas12a (FnCas12a) gene was first integrated into the U32 genome to generate target-specific double-stranded DNA (dsDNA) breaks (DSBs) under the guidance of CRISPR RNAs (crRNAs). Then, the DSBs could be repaired by either the non-homologous DNA end-joining (NHEJ) system or the homology-directed repair (HDR) pathway, generating inaccurate or accurate mutations in target genes, respectively. Besides of A. mediterranei, the present work may also shed light on the development of CRISPR-assisted genome editing systems in other species of the Amycolatopsis genus.

| S-EPMC7332547 | biostudies-literature

Amycolatopsis mediterranei

Project description:Amycolatopsis mediterranei Raw sequence reads

| PRJNA1091067 | ENA

Conjugation of ϕBT1-derived integrative plasmid pDZL802 in Amycolatopsis mediterranei U32.

Project description:The genus Amycolatopsis is well known for its ability to produce antibiotics, and an increasing number of valuable biotechnological applications, such as bioremediation, biodegradation, bioconversion, and potentially biofuel, that use this genus have been developed. Amycolatopsis mediterranei is an industrial-scale producer of the important antibiotic rifamycin, which plays a vital role in antimycobacterial therapy. Genetic studies of Amycolatopsis species have progressed slowly due to the lack of efficient transformation methods and stable plasmid vectors. In A. mediterranei U32, electroporation and replicable plasmid vectors have been developed. Here, we establish a simple and efficient conjugal system by transferring integrative plasmid pDZL802 from ET12567 (pUZ8002) to A. mediterranei U32, with an efficiency of 4 × 10-5 CFU per recipient cell. This integrative vector, based on the ϕBT1 int-attP locus, is a stable and versatile tool for A. mediterranei U32, and it may also be applicable to various other Amycolatopsis species for strain improvement, heterologous protein expression, and synthetic biology experiments.

| S-EPMC5639847 | biostudies-literature

Whole genome sequence of the rifamycin B-producing strain Amycolatopsis mediterranei S699.

Project description:Amycolatopsis mediterranei S699 is an actinomycete that produces an important antibiotic, rifamycin B. Semisynthetic derivatives of rifamycin B are used for the treatment of tuberculosis, leprosy, and AIDS-related mycobacterial infections. Here, we report the complete genome sequence (10.2 Mb) of A. mediterranei S699, with 9,575 predicted coding sequences.

| S-EPMC3187414 | biostudies-literature

Actinosynnema mirum DSM 43827

Project description:Antibiotic-producing bacterium

| PRJNA19705 | ENA

Streptomyces avermitilis

Project description:Antibiotic-producing bacterium

| PRJNA35119 | ENA

Streptomyces ambofaciens

Project description:Antibiotic-producing bacterium

| PRJNA35239 | ENA

Streptomyces griseus subsp. griseus NBRC 13350

Project description:Antibiotic producing bacterium